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, related to Figure 1 and Table S1 . A 5µM stock solution of mimic was prepared in sterile RNAse free dH2O.
Microinjections were performed by injecting MO and/or mimic (5nl) into each blastomere of 2 cell stage Xenopus laevis embryos. Morpholinos were titrated to the following optimal amounts for injection per embryo: miR-142-3p MO and mismatch MO, 100ng; miR-142-5p MO, 50ng; and for the dgcr8 MO, 12-15ng was the optimal sub-lethal dose for analysis of DLP defects at stage 26-32, while 10-12ng gave optimal survival to stage 39 for assessing runx1 expression in the DA. miR-142-3p mimic was titrated to 10-12.5 fmol to provide optimal rescue of dgcr8 morphants when co-injected with the dgcr8 MO, with minimal toxicity.
miRNA profiling and qPCR
Total RNA was prepared from primary mouse cells using the miRVana RNA extraction kit and total RNA was extracted from Xenopus tissues and embryos using TRIzol (Life Technologies). All RNA samples were treated with DNase I to remove genomic DNA. Megaplex primer pools were used to perform reverse transcription and pre-amplification of mouse RNA samples and miRNA profiling was performed using Taqman ChIP-Seq peak data for ten hematopoietic TFs in mouse hematopoietic progenitors was obtained from a published dataset (Wilson et al., 2010) . The number of peaks were scored for each TF within +/-5kb of the mouse pre-miRNA loci obtained from miRBase (www.mirbase.org, Kozomara and Griffiths-Jones, 2011) .
Treatments with inhibitors
TGFβ-type-I-receptor-kinase inhibitors used were SB431542 (Sigma) and LY2157299 (Axon MedChem). 10mM stocks in DMSO were prepared and added to 0.1x MBS to the required concentration. An equivalent volume of DMSO alone was used as the control. Embryos were treated from stage 16-17 to avoid possible earlier effects of the inhibitors on gastrulation and neither inhibitor was toxic at the concentrations used. 
